Cover Image
市場調查報告書

Impax Laboratories, Inc.:產品臨床實驗分析

Impax Laboratories, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 200965
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
Impax Laboratories, Inc.:產品臨床實驗分析 Impax Laboratories, Inc. - Product Pipeline Review - 2014
出版日期: 2014年02月28日 內容資訊: 英文 39 Pages
簡介

本報告針對Impax Laboratories, Inc.治療藥開發臨床實驗現況與各開發階段比較分析、提供藥劑標的、作用程序、投藥過程、分子種類分類治療藥評價、最新企業新聞發表、後期階段與中止方案相關資料。

Impax Laboratories, Inc.基本情報

Impax Laboratories, Inc.概要

  • 主要情報
  • 企業情報

Impax Laboratories, Inc.:R&D概要

  • 主要治療範圍

Impax Laboratories, Inc.:臨床實驗回顧

  • 開發階段分類臨床實驗產品
  • 單劑產品
  • 併用療法模式

Impax Laboratories, Inc.:臨床實驗產品概況

  • 後期臨床實驗產品
    • 申請被拒/停售產品/併用療法模式
    • 第III期產品/併用療法模式
  • 測試階段臨床實驗產品
    • 第II期產品/併用療法模式
    • 第I期產品/併用療法模式

Impax Laboratories, Inc.:藥劑檔案

  • (carbidopa + levodopa)
  • bupivacaine Patch
  • IPX-203
  • IPX-218
  • IPX-231
  • IPX-232
  • IPX-233
  • IPX-237

Impax Laboratories, Inc.:臨床實驗分析

  • 標的分類
  • 投藥通路分類
  • 分子種類分類
  • 作用排序分類

Impax Laboratories, Inc.:最近臨床實驗動向

Impax Laboratories, Inc.:暫停方案

Impax Laboratories, Inc.:開發中止的臨床實驗產品

  • 開發中止的臨床實驗產品檔案
    • IPX-159

Impax Laboratories, Inc.:企業發表

Impax Laboratories, Inc.:總公司與子公司所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04680CDB

Global Markets Direct's, 'Impax Laboratories, Inc. - Product Pipeline Review - 2014', provides an overview of the Impax Laboratories, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Impax Laboratories, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Impax Laboratories, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Impax Laboratories, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Impax Laboratories, Inc.'s pipeline products

Reasons to buy

  • Evaluate Impax Laboratories, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Impax Laboratories, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Impax Laboratories, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Impax Laboratories, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Impax Laboratories, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Impax Laboratories, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Impax Laboratories, Inc. Snapshot
    • Impax Laboratories, Inc. Overview
    • Key Information
    • Key Facts
  • Impax Laboratories, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Impax Laboratories, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Impax Laboratories, Inc. - Pipeline Products Glance
    • Impax Laboratories, Inc. - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Impax Laboratories, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • Impax Laboratories, Inc. - Drug Profiles
    • (carbidopa + levodopa)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bupivacaine Patch
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IPX-203
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IPX-218
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IPX-231
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IPX-232
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IPX-233
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IPX-237
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Impax Laboratories, Inc. - Pipeline Analysis
    • Impax Laboratories, Inc. - Pipeline Products by Target
    • Impax Laboratories, Inc. - Pipeline Products by Route of Administration
    • Impax Laboratories, Inc. - Pipeline Products by Molecule Type
    • Impax Laboratories, Inc. - Pipeline Products by Mechanism of Action
  • Impax Laboratories, Inc. - Recent Pipeline Updates
  • Impax Laboratories, Inc. - Dormant Projects
  • Impax Laboratories, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • IPX-159
  • Impax Laboratories, Inc. - Company Statement
  • Impax Laboratories, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Impax Laboratories, Inc., Key Information
  • Impax Laboratories, Inc., Key Facts
  • Impax Laboratories, Inc. - Pipeline by Indication, 2014
  • Impax Laboratories, Inc. - Pipeline by Stage of Development, 2014
  • Impax Laboratories, Inc. - Monotherapy Products in Pipeline, 2014
  • Impax Laboratories, Inc. - Combination Treatment Modalities in Pipeline, 2014
  • Impax Laboratories, Inc. - Filing rejected/Withdrawn, 2014
  • Impax Laboratories, Inc. - Phase III, 2014
  • Impax Laboratories, Inc. - Phase II, 2014
  • Impax Laboratories, Inc. - Phase I, 2014
  • Impax Laboratories, Inc. - Pipeline by Target, 2014
  • Impax Laboratories, Inc. - Pipeline by Route of Administration, 2014
  • Impax Laboratories, Inc. - Pipeline by Molecule Type, 2014
  • Impax Laboratories, Inc. - Pipeline Products by Mechanism of Action, 2014
  • Impax Laboratories, Inc. - Recent Pipeline Updates, 2014
  • Impax Laboratories, Inc. - Dormant Developmental Projects,2014
  • Impax Laboratories, Inc. - Discontinued Pipeline Products, 2014
  • Impax Laboratories, Inc., Other Locations
  • Impax Laboratories, Inc., Subsidiaries

List of Figures

  • Impax Laboratories, Inc. - Pipeline by Top 10 Indication, 2014
  • Impax Laboratories, Inc. - Pipeline by Stage of Development, 2014
  • Impax Laboratories, Inc. - Monotherapy Products in Pipeline, 2014
  • Impax Laboratories, Inc. - Combination Treatment Modalities in Pipeline, 2014
  • Impax Laboratories, Inc. - Pipeline by Top 10 Target, 2014
  • Impax Laboratories, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Impax Laboratories, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Impax Laboratories, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top